CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Tumour-infiltrating lymphocytes do not predict survival in human papillomavirus-associated oropharyngeal squamous cell carcinoma: a single institution retrospective review.
Tumour-infiltrating lymphocytes do not predict survival in human papillomavirus-associated oropharyngeal squamous cell carcinoma: a single institution retrospective review.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
HPV+OPSCC 中 TIL 密度已被报道可预测生存结局。本研究结果不支持这一观点。采用标准化评分技术进行进一步前瞻性评估,可能充分揭示 TILs 在 HPV+OPSCC 中的预后价值。
人乳头瘤病毒(HPV)相关口咽鳞状细胞癌(OPSCC)与非HPV OPSCC相比预后较好。TIL(肿瘤浸润淋巴细胞)(TILs)可能预测HPV+OPSCC患者更好的生存结局。
对2003-2018年间接受治疗的HPV+OPSCC患者进行回顾性分析。确定每位患者肿瘤标本的TIL密度评分。将患者分为TIL-Hi或TIL-Lo。比较两个TIL组的生存结局。
共纳入57例患者,其中TIL-Hi组33例。TIL-Hi组和TIL-Lo组的5年总生存率分别为81.8%和75%。5年疾病特异性生存率分别为87.9%和87.5%。TIL-Hi组与TIL-Lo组之间的生存结局无统计学显著差异。
Human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma (OPSCC) exhibits a favourable prognosis compared to non-HPV OPCSCC. Tumour infiltrating lymphocytes (TILs) may predict better survival outcomes for patients with HPV+OPSCC.
A retrospective review of patients treated for HPV+OPSCC between 2003-2018. TIL density scores for each patient's tumour specimen were determined. Patients were categorised as TIL-Hi or TIL-Lo. Survival outcomes for the two TIL groups were compared.
Fifty-seven patients, 33 in the TIL-Hi group, were included. 5-year overall survival was 81.8% in the TIL-Hi and 75% in the TIL-Lo groups. 5-year disease specific survival was 87.9% and 87.5%, respectively. There was no statistically significant difference in survival outcomes between TIL-Hi and TIL-Lo.
TIL density in HPV+OPSCC has been reported to predict survival outcomes. This is not supported by the findings of this study. Further prospective evaluation with a standardised scoring technique may fully elicit the prognostic value of TILs in HPV+OPSCC.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。